{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:08:17Z","timestamp":1792512497332,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:00Z","timestamp":1760140800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Metabolism"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.molmet.2025.102271","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:58:18Z","timestamp":1760662698000},"page":"102271","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept"],"prefix":"10.1016","volume":"102","author":[{"given":"Daniel A.","family":"Briere","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongchang","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Lansu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minxia Michelle","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie S.","family":"Moyers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamer","family":"Coskun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libbey","family":"O'Farrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Breanna","family":"Bowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Pratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Tidemann-Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lai San","family":"Tham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilda","family":"Ibriga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Alsina-Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieren J.","family":"Mather","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Haupt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shobha N.","family":"Bhattachar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.molmet.2025.102271_bib1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/17446651.2021.1991310","article-title":"Understanding the pathophysiologic pathways that underlie obesity and options for treatment","volume":"16","author":"Kumar","year":"2021","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.molmet.2025.102271_bib2","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.1111\/dom.15796","article-title":"The role of incretin receptor agonists in the treatment of obesity","volume":"26","author":"Forst","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1016\/j.molmet.2025.102271_bib3","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s13300-024-01566-x","article-title":"Dual and triple incretin-based Co-agonists: novel therapeutics for obesity and diabetes","volume":"15","author":"Gutgesell","year":"2024","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.molmet.2025.102271_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2024.171219","article-title":"Glucagon-based therapy for people with diabetes and obesity: what is the sweet spot?","volume":"176","author":"McGlone","year":"2024","journal-title":"Peptides"},{"key":"10.1016\/j.molmet.2025.102271_bib5","doi-asserted-by":"crossref","DOI":"10.1002\/jcph.2487","article-title":"Pharmacotherapy of weight-loss and obesity with a focus on GLP 1-Receptor agonists","author":"Myerson","year":"2024","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.molmet.2025.102271_bib6","article-title":"Amylin and calcitonin: potential therapeutic strategies to reduce body weight and liver fat","volume":"11","author":"Mathiesen","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.molmet.2025.102271_bib7","doi-asserted-by":"crossref","DOI":"10.1038\/s41574-025-01125-9","article-title":"Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus","author":"Walker","year":"2025","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"10.1016\/j.molmet.2025.102271_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25031517","article-title":"Amylin, another important neuroendocrine hormone for the treatment of diabesity","volume":"25","author":"Er\u017een","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.molmet.2025.102271_bib9","doi-asserted-by":"crossref","first-page":"189","DOI":"10.4239\/wjd.v7.i9.189","article-title":"Neuroendocrine hormone amylin in diabetes","volume":"7","author":"Zhang","year":"2016","journal-title":"World J Diabetes"},{"key":"10.1016\/j.molmet.2025.102271_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.appet.2022.105965","article-title":"Creating the amylin story","volume":"172","author":"Lutz","year":"2022","journal-title":"Appetite"},{"issue":"1","key":"10.1016\/j.molmet.2025.102271_bib11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/bph.14075","article-title":"Update on the pharmacology of calcitonin\/CGRP family of peptides: IUPHAR review 25","volume":"175","author":"Hay","year":"2018","journal-title":"Br J Pharmacol"},{"issue":"8","key":"10.1016\/j.molmet.2025.102271_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11082207","article-title":"Mediators of amylin action in metabolic control","volume":"11","author":"Boyle","year":"2022","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.molmet.2025.102271_bib13","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/0031-9384(95)02067-5","article-title":"Amylin decreases meal size in rats","volume":"58","author":"Lutz","year":"1995","journal-title":"Physiol Behav"},{"issue":"3","key":"10.1016\/j.molmet.2025.102271_bib14","doi-asserted-by":"crossref","DOI":"10.1096\/fba.2024-00151","article-title":"The role of amylin, a gut-brain axis hormone, in metabolic and neurological disorders","volume":"7","author":"Muhammad","year":"2025","journal-title":"FASEB Bioadv"},{"issue":"5","key":"10.1016\/j.molmet.2025.102271_bib15","doi-asserted-by":"crossref","first-page":"R1395","DOI":"10.1152\/ajpregu.00597.2001","article-title":"Effects of amylin-related peptides on food intake, meal patterns, and gastric emptying in rats","volume":"282","author":"Reidelberger","year":"2002","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"1","key":"10.1016\/j.molmet.2025.102271_bib16","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1152\/physrev.00066.2017","article-title":"The activity of peptides of the calcitonin family in bone","volume":"99","author":"Naot","year":"2019","journal-title":"Physiol Rev"},{"key":"10.1016\/j.molmet.2025.102271_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101109","article-title":"Mono and dual agonists of the amylin, calcitonin, and CGRP receptors and their potential in metabolic diseases","volume":"46","author":"Sonne","year":"2021","journal-title":"Mol Metab"},{"issue":"8","key":"10.1016\/j.molmet.2025.102271_bib18","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1210\/jc.2006-2003","article-title":"Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study","volume":"92","author":"Aronne","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.molmet.2025.102271_bib19","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.2337\/dc08-0029","article-title":"Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity","volume":"31","author":"Smith","year":"2008","journal-title":"Diabetes Care"},{"issue":"10286","key":"10.1016\/j.molmet.2025.102271_bib20","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(21)00845-X","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2\u00b74 mg for weight management: a randomised, controlled, phase 1b trial","volume":"397","author":"Enebo","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.molmet.2025.102271_bib21","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1124\/jpet.121.000567","article-title":"AM833 is a novel agonist of calcitonin family G protein-coupled receptors: pharmacological comparison with six selective and nonselective agonists","volume":"377","author":"Fletcher","year":"2021","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.molmet.2025.102271_bib22","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2502081","article-title":"Coadministered cagrilintide and semaglutide in adults with overweight or obesity","author":"Garvey","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.molmet.2025.102271_bib23","unstructured":"US Food and Drug Administration. MIACALCIN (Calcitonin-salmon) nasal spray. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/020313s036lbl.pdf. Accessed on July 18, 2025."},{"key":"10.1016\/j.molmet.2025.102271_bib24","unstructured":"US Food and Drug Administration. MIACALCIN (calcitonin-salmon) injection. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/017808s034lbl.pdf. Accessed on July 18, 2025."},{"issue":"6","key":"10.1016\/j.molmet.2025.102271_bib25","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/d41573-025-00088-w","article-title":"Amylin takes another shot at the obesity prize","volume":"24","author":"Mullard","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.molmet.2025.102271_bib26","article-title":"Long acting amylin receptor agonists and uses thereof","volume":"II","author":"Abraham","year":"2022","journal-title":"Compound"},{"issue":"47","key":"10.1016\/j.molmet.2025.102271_bib27","doi-asserted-by":"crossref","first-page":"13505","DOI":"10.1021\/bi701427q","article-title":"Peptide conformation and supramolecular organization in amylin fibrils: constraints from solid-state NMR","volume":"46","author":"Luca","year":"2007","journal-title":"Biochemistry"},{"issue":"4","key":"10.1016\/j.molmet.2025.102271_bib28","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3109\/13506129.2011.627956","article-title":"Ferret islet amyloid polypeptide (IAPP): characterization of in vitro and in vivo amyloidogenicity","volume":"18","author":"Paulsson","year":"2011","journal-title":"Amyloid"},{"issue":"1","key":"10.1016\/j.molmet.2025.102271_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12010145","article-title":"Clinical recommendations to manage gastrointestinal adverse events in patients treated with Glp-1 receptor agonists: a multidisciplinary expert consensus","volume":"12","author":"Gorgojo-Mart\u00ednez","year":"2022","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.molmet.2025.102271_bib30","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13543","article-title":"Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: a network meta-analysis of randomized clinical trials","volume":"24","author":"Alkhezi","year":"2023","journal-title":"Obes Rev"},{"issue":"11","key":"10.1016\/j.molmet.2025.102271_bib31","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.molmet.2025.102271_bib32","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"10317","key":"10.1016\/j.molmet.2025.102271_bib33","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/S0140-6736(21)01751-7","article-title":"Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial","volume":"398","author":"Lau","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.molmet.2025.102271_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101444","article-title":"Hypophagia induced by salmon calcitonin, but not by amylin, is partially driven by malaise and is mediated by CGRP neurons","volume":"58","author":"Boccia","year":"2022","journal-title":"Mol Metab"},{"issue":"5","key":"10.1016\/j.molmet.2025.102271_bib35","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0196-9781(02)00022-0","article-title":"Acute 3rd-ventricular amylin infusion potently reduces food intake but does not produce aversive consequences","volume":"23","author":"Rushing","year":"2002","journal-title":"Peptides"},{"key":"10.1016\/j.molmet.2025.102271_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105836","article-title":"Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3","volume":"118","author":"Carvas","year":"2025","journal-title":"EBioMedicine"},{"key":"10.1016\/j.molmet.2025.102271_bib37","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.neuroscience.2019.11.036","article-title":"RAMP1 and RAMP3 differentially control amylin's effects on food intake, glucose and energy balance in Male and female mice","volume":"447","author":"Coester","year":"2020","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.molmet.2025.102271_bib38","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/dom.16012","article-title":"Characterizing body composition modifying effects of a glucagon-like peptide 1 receptor-based agonist: a meta-analysis","volume":"27","author":"Jiao","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"10.1016\/j.molmet.2025.102271_bib39","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1111\/dom.15113","article-title":"Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: a randomized trial in adults with obesity and prediabetes","volume":"25","author":"Silver","year":"2023","journal-title":"Diabetes Obes Metab"}],"container-title":["Molecular Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212877825001784?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212877825001784?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T12:36:55Z","timestamp":1764765415000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212877825001784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":39,"alternative-id":["S2212877825001784"],"URL":"https:\/\/doi.org\/10.1016\/j.molmet.2025.102271","relation":{},"ISSN":["2212-8778"],"issn-type":[{"value":"2212-8778","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept","name":"articletitle","label":"Article Title"},{"value":"Molecular Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmet.2025.102271","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"102271"}}